Revenue- Narrative (Details)				1 Months Ended	3 Months Ended		6 Months Ended	102 Months Ended
	May 28, 2021 USD ($)	Aug. 03, 2020 USD ($) shares	Jan. 07, 2018 USD ($)	Oct. 31, 2014	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2023 USD ($)	Oct. 01, 2014 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Expenses related to collaboration agreement					$ 126,683,000	$ 130,976,000
Unrealized gain (loss) on available-for-sale investments					2,043,000	(4,802,000)
Total revenue					7,167,000	709,000
Product Revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total revenue					6,291,000	0
Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Expenses related to collaboration agreement						0
BeiGene Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable, non-creditable up-front fee			$ 10,000,000
Milestone payments			$ 123,000,000
Termination of contract, period after first commercial sale of product			10 years
Period required for notice of termination of contract			60 days
Performance obligation, compensation to be earned			$ 500,000
Milestone payments earned					0	0
Royalty revenue					0	0
BeiGene Agreement | Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty percentage rate (up to)			0.20
BeiGene Agreement | Licenses of Intellectual Property
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Performance obligation, compensation to be earned			$ 9,500,000
BeiGene Agreement | Manufacturing Supply Services
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized					0
Pfizer Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Termination of contract, period after first commercial sale of product				10 years
Period required for notice of termination of contract				60 days
Pfizer Agreement | Development Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential development milestone payments									$ 9,300,000
Development milestone payments					1,000,000			$ 10,500,000
Pfizer Agreement | Sales Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential development milestone payments									$ 337,000,000
Pfizer Agreement | Milestone Payments - First Commercial Sale of KRAZATI
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential development milestone payments					15,000,000			15,000,000
Pfizer Agreement | Royalties
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential development milestone payments					500,000			$ 500,000
ORIC Pharmaceuticals Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock received as part of stock issuance and license agreements (shares) | shares		588,235
License agreement, period of transfer restrictions		18 months
License agreement, period of agreement after first commercial sale		10 years
ORIC Pharmaceuticals Agreement | Level 3
Research and Development Arrangement, Contract to Perform for Others [Line Items]
One-time non-cash payment		$ 11,400,000
Zai Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Period required for notice of termination of contract	12 months
Milestone payments earned					0
Termination of contract, period after first commercial sale of product	10 years
Up-front fee received	$ 65,000,000
Transaction price of arrangement	66,600,000
Zai Agreement | Licenses of Intellectual Property
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized							$ 66,600,000
Income tax recovery							$ 3,300,000
Zai Agreement | Manufacturing Supply Services
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized					900,000	700,000
Zai Agreement | Sales Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from performance obligation expected to be earned	180,000,000
Zai Agreement | Development and Regulatory Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from performance obligation expected to be earned	$ 93,000,000
Zai Agreement | Royalties
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty revenue					$ 0	$ 0